Medical specialists from Canada tagged as investigators in clinical trials studying Neisseria Meningitidis Infection

Total 3 results

Natalie Bridger, MD
Seen in:
- Newfoundland and Labrador, Saint John's, Eastern Health Janeway Children's and Rehabilitation Centre
Trials:
- NCT04184336 (Principal Investigator)
Conditions:
- Invasive Meningococcal Disease
Roseline Thibeault
Seen in:
- Quebec, Québec, Centre Mere-Enfant Soleil CHU de Quebec
Trials:
- NCT04184336 (Principal Investigator)
Conditions:
- Invasive Meningococcal Disease
Shaun Morris
Seen in:
- Ontario, Toronto, The Hospital for Sick Children
Trials:
- NCT04184336 (Principal Investigator)
Conditions:
- Invasive Meningococcal Disease

Clinical Trials on Neisseria Meningitidis Infection

Pfizer

Completed

NeisVac-C Single Prime Study in Infants

Neisseria Meningitidis

Poland, Spain
Public Health England

Completed

Immunogenicity and Reactogenicity of a Meningococcal B Outer Membrane Vesicle Vaccine Given in a 0,6,12 Month Schedule to Health UK Adults

Neisseria Meningitidis
University Hospital, Rouen
Institut Pasteur; Direction Générale de la Santé, France

Completed

Evaluation of Immune Response Against the Strain of Neisseria Meningitidis B: 14, P1-7, 16 in Patients Having to be Vaccinated MenBVac® (Extension EFFIVAC) (Exten Effivac)

Neisseria Meningitidis

France
Public Health England

Completed

Meningococcal B Vaccination in University Students (MNB3)

Neisseria Meningitidis Serogroup B

United Kingdom
University of Adelaide

Completed

Study to Assess Oropharyngeal Carriage of N. Meningitidis in South Australian School Leavers (B Part Of It)

Neisseria Meningitidis

Australia
GlaxoSmithKline

Completed

Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age

Neisseria Meningitidis | Haemophilus Influenzae Type b

United States
GlaxoSmithKline

Completed

Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years.

Neisseria Meningitidis | Haemophilus Influenzae Type b

Australia
GlaxoSmithKline

Completed

Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine

Neisseria Meningitidis | Haemophilus Influenzae Type b

United States
GlaxoSmithKline

Completed

Long-Term Antibody Persistence at 1, 3 and 5 Years After a Fourth Dose of GSK Biologicals' Hib-MenCY-TT Vaccine Compared to ActHIB

Neisseria Meningitidis | Haemophilus Influenzae Type b

United States
GlaxoSmithKline

Completed

Long-term Persistence Study to Assess a Booster Dose of GSK Biologicals' Hib-MenC

Neisseria Meningitidis | Haemophilus Influenzae Type b

Spain

Medical specialists from Canada tagged as investigators in clinical trials studying Neisseria Meningitidis Infection

Clinical Trials on Neisseria Meningitidis Infection

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritius

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations